NYSE : ANRO
Alto Neuroscience, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 22.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 886.87M |
| Enterprise Value | 666.43M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 39.24M |
| Shares Outstanding | 39.24M |
| Shares Change (YoY) | +31.27% |
| Shares Change (QoQ) | +30.16% |
| Owned by Insiders (%) | 2.51% |
| Owned by Institutions (%) | 64.63% |
| Float | 29.59M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.62 |
| P/TBV Ratio | 4.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.85 |
| Quick Ratio | 14.64 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.04 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -49.17% |
| Return on Assets (ROA) | -26.79% |
| Return on Invested Capital (ROIC) | -28.06% |
| Return on Capital Employed (ROCE) | -37.18% |
| Weighted Average Cost of Capital (WACC) | 11.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +60.97% |
| 50-Day Moving Average | 28.27 |
| 200-Day Moving Average | 24.26 |
| Relative Strength Index (RSI) | 39.66 |
| Average Volume (20 Days) | 616,856 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.20M |
| Short Previous Month | 4.17M |
| Short % of Shares Out | 13.26% |
| Short % of Float | 17.59% |
| Short Ratio (days to cover) | 7.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -88.27M |
| Pretax Income | -84.24M |
| Net Income | -84.24M |
| EBITDA | -87.58M |
| EBIT | -88.27M |
| Earnings Per Share (EPS) | -$2.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 243.73M |
| Total Debt | 23.29M |
| Net Cash | 220.44M |
| Net Cash Per Share | $5.62 |
| Equity (Book Value) | 219.25M |
| Book Value Per Share | 6.25 |
| Working Capital | 230.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -68.29M |
| Capital Expenditures | -556,000 |
| Depreciation & Amortization | 689,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -68.84M |
| FCF Per Share | -$1.75 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.27% |
| Shareholder Yield | -31.27% |
| Earnings Yield | -10.53% |
| FCF Yield | -7.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $38.67 |
| Price Target Difference | 71.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |